6 investors discuss why AI is more than just a buzzword in biotech
TechCrunch
DECEMBER 15, 2022
“Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. The NASDAQ Biotechnology Index peaked in 2021. How has due diligence in this space changed in 2022? Robert Mittendorff, M.D,
Let's personalize your content